Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5433248 | 1.00 | EPHX1 (0.44) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL5433245 | 1.00 | EPHX1 (0.44) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL17504487 | 1.00 | EPHX1 (0.44) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL27779679 | 0.91 | BTK (0.39) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL897214 | 0.89 | — | — | |
| SCHEMBL15970550 | 0.89 | POLB (0.41) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL5007222 | 0.89 | POLB (0.41) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL10274166 | 0.89 | BTK (0.41) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL25262798 | 0.86 | TRPV1 (0.39) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL14689304 | 0.86 | TRPV1 (0.39) | EPHX1NPC1SMN1; SMN2RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185079-A1 | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185119-A1 | Therapeutic agents II | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185119-A1 | Therapeutic agents II | HTT, ACHE, GPR119 | EPHX1 287/4885NPC1 105/4885SMN1; SMN2 57/4885 |
| US-20070185079-A1 | Therapeutic agents I | HTT, GRIN2A, GRIN1 | EPHX1 568/4885NPC1 106/4885SMN1; SMN2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.